Sulcoflex Trifocal
For presbyopia correction, Rayner’s solution is to combine the technologies of two advanced IOL systems – Sulcoflex and RayOne Trifocal. Sulcoflex IOLs are designed to be implanted in the ciliary sulcus as a pseudophakic supplementary IOL, and are validated by over 10 years of clinical success; the RayOne Trifocal reduces light loss to 11 percent, and – by virtue of having fewer rings and a patented optic surface – reduces potential visual disturbances and improves night vision compared with other trifocal IOLs. Amalgamating these two unique technologies into a single lens – the Sulcoflex Trifocal supplementary IOL – enables surgeons to correct presbyopia (DUET procedure) and fine-tune the postsurgical outcome, which, in turn, relaxes patient selection criteria. It can be removed with ease, and therefore offers an adjustable solution for patients who desire a spectacle-free lifestyle. Sulcoflex Trifocal is not limited to new aphakic patients; it is also the first supplementary IOL that can provide state-of-the-art trifocal technology to pseudophakic patients.
RayPRO
All Rayner IOLs, including those with the latest trifocal technology, will be supported by the RayPRO digital platform. This free resource for Rayner users – informed by best practices taken from successful fitness apps like Strava and Garmin Connect – proactively collects Patient Reported Outcomes (PROs) over three years. During this period, patients receive five simple email questionnaires covering: i) satisfaction, ii) spectacle independence, iii) refractive achievement, iv) visual disturbances, and v) requirement for additional procedures, for example Nd:YAG or laser top-up. Each questionnaire takes less than five minutes to complete and can be done from home.
Anonymized PRO data are compiled into clear reports that surgeons can access from anywhere, via a web browser or the RayPRO smartphone app. Results can be filtered by date, hospital and IOL model to identify trends by time, location or product. RayPRO’s intelligent algorithm also calculates a personal score from a combination of metrics allowing surgeons to rank themselves against peers. Thus, RayPRO allows surgeons to monitor longer-term outcomes and patient satisfaction – information that post- operative visual acuity and refractive attainment data alone cannot reveal. Furthermore, it removes the burden of PRO collection from the surgeon.
One key driver behind RayPRO is Rayner’s vision to give surgeons on-demand access to surgical outcome measures in the same way that other information can be instantly accessed at any time via smartphones. But it won’t end there; as Rayner CEO, Tim Clover says: “RayPRO will generate data-driven insights into product performance and trends, and will help ophthalmology join other healthcare fields in exploiting ‘big data’ to advance patient care.” In this way, RayPRO – together with the level of control over presbyopia correction provided by the Sulcoflex Trifocal IOL – truly positions Rayner as a provider of total solutions in the IOL space.
Sulcoflex Trifocal (launched 2018) is CE-marked, but not FDA-cleared. RayPRO will be launched globally in early 2019, with patient questionnaires initially available in English, French, German, Italian, Spanish and Portuguese.
